470454-73-0

470454-73-0 structure

Name: F15845
Chemical Name: (3R)-N-[(2S)-3-(2-methoxyphenyl)sulfanyl-2-methylpropyl]-3,4-dihydro-2H-1,5-benzoxathiepin-3-amine
CAS Number: 470454-73-0
Molecular Formula: C₂₀H₂₅NO₂S₂
Molecular Weight: 375.54800
Catalog: Signaling Pathways Membrane Transporter/Ion Channel Sodium Channel
Create Date: 2017-03-06 02:13:06
Modify Date: 2024-01-10 13:17:36
F 15845 is a highly effective persistent sodium current blocker. F 15845 also is a cardioprotective agent, has anti-ischemic activity and exerts short- and long-term cardioprotection after myocardial infarction. F 15845 can be used for the research of myocardium functional impairment[1].

Name	(3R)-N-[(2S)-3-(2-methoxyphenyl)sulfanyl-2-methylpropyl]-3,4-dihydro-2H-1,5-benzoxathiepin-3-amine
Synonyms	UNII-937TSH5BGH 3-(R)-((3-((2-Methoxyphenyl)thio)-2-(S)-methylpropyl)amino)-3,4-dihydro-2H-1,5-benzoxathiepin (3R)-N-((2S)-3-((2-Methoxyphenyl)sulfanyl)-2-methylpropyl)-3,4-dihydro-2H-1,5-benzoxathiepin-3-amine 2H-1,5-Benzoxathiepin-3-amine,3,4-dihydro-N-((2S)-3-((2-methoxyphenyl)thio)-2-methylpropyl)-,(3R)

Description	F 15845 is a highly effective persistent sodium current blocker. F 15845 also is a cardioprotective agent, has anti-ischemic activity and exerts short- and long-term cardioprotection after myocardial infarction. F 15845 can be used for the research of myocardium functional impairment[1].
Related Catalog	Signaling Pathways >> Membrane Transporter/Ion Channel >> Sodium Channel Research Areas >> Cardiovascular Disease
In Vitro	F 15845 (10 nM-10 μM) concentration-dependently reduces veratrine-induced diastolic contracture with an IC50 value of 0.14 μM in isolated atria[1]. F 15845 (0.1-10 μM) preserves viability in isolated cardiomyocytes exposed to lysophosphatidylcholine (LPC)[1]. F 15845 (0.3 μM) significantly counteracts [Na+] increase during no-flow ischemia[1]. F 15845 (0.3 μM, 0-35 min) delays the reduction in [Na+], but marks and maintains upon reperfusion[1].
In Vivo	F 15845 (i.v.; 5 mg/kg) exhibits remarkable cardioprotective properties in anesthetized rat[1]. Animal Model: Rat[1] Dosage: 2.5 mg/kg, 5 mg/kg Administration: intravenously Result: Significantly reduced infarct size, decreased of troponin I levels and limited the long-term expansion of infarct size.
References	[1]. Bruno Vié, et al. 3-(R)-[3-(2-methoxyphenylthio-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine bromhydrate (F 15845) prevents ischemia-induced heart remodeling by reduction of the intracellular Na+ overload. J Pharmacol Exp Ther. 2009 Sep;330(3):696-703.